Folia Microbiologica

, 50:467 | Cite as

Antimicrobial activity of 1,2-bis-[2-(5-R)-1H-benzimidazolyl]-1,2-ethanediols, 1,4-bis-[2-(5-R)-1H-benzimidazolyl]-1,2,3,4-butanetetraols and their FeIII, CuII, and AgI complexes

  • A. Tavman
  • S. Birteksöz
  • G. Ötük
Article

Abstract

1,2-Bis-[2-(5-H/Me/Cl/NO2)-1H-benzimidazolyl]-1,2-ethanediols (L 1L 4), 1,4-Bis-[2-(5-H/Me/Cl)-1H-benzimidazolyl]-1,2,3,4-butanetetraols (L 5L 7) and their complexes with FeCl3, CuCl2, and AgNO3 were synthesized; antibacterial activity of the compounds was determined towardStaphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhi, Shigella flexneri, Proteus mirabilis, and antifungal activity againstCandida albicans. The AgI complexes have considerable activity toward the microorganisms. Some AgI complexes show higher activity towardS. epidermidis than AgNO3 and cefuroxime. Cu(L 3)Cl2 and Fe(L 3)Cl3 show an antifungal effect onC. albicans butL 3 itself has no activity.

References

  1. Agh-Atabay N.M., Dulger B., Gucin F.: Synthesis and investigation of antimicrobial activity of some bis-benzimidazole-derived chelating agents.Eur.J.Med.Chem. 38, 875–881 (2003).PubMedCrossRefGoogle Scholar
  2. Akihama S., Takahashi K., Miyajama N.: Antiviral activity of benzimidazole derivatives. IV. Bisbenzimidazole derivatives.Yakugaku Zasshi 94, 247–251 (1974);Chem.Abstr. 81, 9648x (1975).PubMedGoogle Scholar
  3. Altisen M.R.C., Constansa J.F.: Use of 2-(4-(azolylbutyl)piperazinyl-(methyl))-benzimidazole derivatives for treating or preventing asthma.French Pat. Appl. 94 714 766 (1996);Chem.Abstr. 125, P132781q (1996).Google Scholar
  4. Çakir B., Büyükbingöl E., Uçucu Ü., Abbasoğlu U., Noyanalpan N.: Benzimidazole derivatives: Bis-benzimidazoles and their antifungal activities.J.Fac.Pharm.Gazi 5, 71–77 (1988a).Google Scholar
  5. Çakir B., Uçucu Ü., Abbasoğlu U.: Benzimidazole derivatives: 5-chloro-2,2′-bis-benzimidazoles, synthesis, antifungal activities and QSARs.J.Fac.Pharm.Gazi 5, 105–110 (1988b).Google Scholar
  6. Chimirri A., Monforte P., Musumeci L., Rao A., Zappala M., Monforte A.M.: Synthesis and antitumour activity of 1H,3H-thiazolo[3,4-a]benzimidazole derivatives.Arch.Pharm. 334, 203–208 (2001).CrossRefGoogle Scholar
  7. Evans D., Hicks T.A., Williamson W.R.N., Dawson W., Meacock S.C.R., Kitchen E.A.: Synthesis of a group of 1H-benzimidazoles and their screening for anti-inflammatory activity.Eur.J.Med.Chem. 31, 635–642 (1996).CrossRefGoogle Scholar
  8. Kim S.U., Kim D.Y., Chung G.J., Hong S.K., Sung J., Nam S.H., Lee S.M.: 5-Pyrrolyl-6-halo-2-(pyridiyl-methylsulfinyl)-benzimidazole gastrointestinal ulcer inhibitors.Korean Pat. Appl. 9 432–612 (1996);Chem.Abstr. 125, P114626p (1996).Google Scholar
  9. Klimešová V., Kočí J., Waisser K., Kaustová J.: New benzimidazole derivatives as antimycobacterial agents.Farmaco 57, 259–265 (2002a).PubMedCrossRefGoogle Scholar
  10. Klimešová V., Koči J., Pour M., Stachel J., Waisser K., Kaustová J.: Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents.Eur.J.Med.Chem. 37, 409–418 (2002b).PubMedCrossRefGoogle Scholar
  11. Küçükbay H., Durmaz B.: Antifungal activity of organic and organometallic derivatives of benzimidazole and benzothiazole.Arzneim.Forsch. 47, 667–670 (1997).Google Scholar
  12. Küçükbay H., Durmaz B., N. Okyucu, S. Günal: Antifungal activity of some bis-5-methylbenzimidazole compounds.Folia Microbiol. 48, 679–681 (2003).CrossRefGoogle Scholar
  13. National Committee for Clinical Laboratory Standards: Methods for dilutions antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A4, Villanova (USA) 1997a.Google Scholar
  14. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27-A, Villanova (USA) 1997b.Google Scholar
  15. O’Sullivan D.G., Wallis A.K.: New benzimidazole derivatives with powerful protective action on tissue-culture alls infected with types 1, 2, and 3 polio virus.Nature 198, 1270–1273 (1963).CrossRefGoogle Scholar
  16. Otaki K., Inoue J., Yamazaki Z., Haya M., Takai Y., Yasue M., Mizuno D.: Screening of antipoliovirus activity of benzimidazole derivatives.Yakugaku Zasshi 85, 926–935 (1965);Chem.Abstr. 64, 2434f (1965).PubMedGoogle Scholar
  17. Rosenfeld D.A., Pratt J.W., Richtmyer N.K., Hudson C.S.: New benzimidazoles from polyhydroxy acids.J.Amer.Chem.Soc. 73, 5907–5908 (1951).CrossRefGoogle Scholar
  18. Seth G., Garg Y.: Biologically important coordination compounds of palladium(II) and platinum(IV) with 2-substituted benzimidazole.Asian J. Chem. 14, 1027–1030 (2002).Google Scholar
  19. Sumiyuki A., Katsuo S.T.: Antipolioviral action of 1,2-bis-(2-benzimidazolyl)-1,2-ethanediol derivatives.Meiji Yakka Daigaku Kenkyu Kiyo 4, 25–28 (1974).Google Scholar
  20. Tavman A., Ülküseven B., Agh-Atabay N.M.: 1,2-Bis-(2-benzimidazolyl)-1,2-ethanediol and 1,4-bis-(2-benzimidazolyl)-1,2,3,4-butanetetraol PdCl2 complexes.Transit.Met.Chem. 25, 324–328 (2000).CrossRefGoogle Scholar
  21. Tavman A., Ülküseven B., Birteksöz S., Ötuk G.: Antimicrobial activity of some 2- and 3-pyridinyl-1H-benzimidazoles and their FeIII, CuII, ZnII, and AgI complexes.Folia Microbiol. 48, 479–483 (2003).CrossRefGoogle Scholar
  22. Ülküseven B., Tavman A., Ötük G., Birteksöz S.: Antimicrobial activity of FeIII, CuII, AgI, ZnII and HgII complexes of 2-(2-hydroxy-5-bromo/nitro-phenyl)-1H- and 2-(2-hydroxyphenyl-5-methyl/chloro/nitro-1H-benzimidazoles).Folia Microbiol. 47, 481–487 (2002).CrossRefGoogle Scholar

Copyright information

© Institute of Microbiology, Academy of Sciences of the Czech Republic 2005

Authors and Affiliations

  • A. Tavman
    • 1
  • S. Birteksöz
    • 2
  • G. Ötük
    • 2
  1. 1.Department of Chemistry, Faculty of EngineeringIstanbul UniversityAvcilar, IstanbulTurkey
  2. 2.Department of Pharmaceutical Microbiology, Faculty of PharmacyIstanbul UniversityBeyazit, IstanbulTurkey

Personalised recommendations